UBS O'Connor’s Astria Therapeutics ATXS Stock Holding History

UBS O'Connor’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-90,000	Closed	-$13.5K	–	545
2024 Q1	$13.5K	Buy	+90,000	New	+$1.12M	﹤0.01%	476

Other funds holding ATXS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

UBS O'Connor's ATXS Position: Q1 2025 in Review

UBS O'Connor sold out of Astria Therapeutics (ATXS) in Q1 2025, closing a stake of 129,666 shares — an estimated $1.16M sold.

UBS O'Connor first reported a position in ATXS in Q2 2023 and held it in 7 quarters. The position peaked at $1.52M in Q1 2024. 115 funds tracked by Wall St. Rank hold ATXS as of Q1 2025.

UBS O'Connor reported no remaining Astria Therapeutics position as of Q1 2025 after selling out during the quarter.
UBS O'Connor sold 129,666 Astria Therapeutics shares in Q1 2025, an estimated $1.16M.
UBS O'Connor first reported a position in Astria Therapeutics in Q2 2023 and held it in 7 quarters.
UBS O'Connor's Astria Therapeutics position peaked at $1.52M in Q1 2024.
115 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2025.

Based on UBS O'Connor's 13F filing for Q1 2025, filed 15 May 2025.